Disclosure Statement: Updates to Cancer Survivorship
All individuals in a position to control the content of this activity have been asked to disclose any relationship they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The following planners, speakers, and content reviewers have reported relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated:
| NAME | COMPANY | RELATIONSHIP |
| Course Faculty: | ||
| Mark M. Awad, MD, PhD | Archer DX | Consultant |
| Ariad | Consultant | |
| Blueprint Medicine | Consultant | |
| Gritstone | Consultant | |
| EMD Serono | Consultant | |
| Maverick | Consultant | |
| Merck | Consultant | |
| Mirati | Consultant | |
| Nektar | Consultant | |
| NextCure | Consultant | |
| Novartis | Consultant | |
| NovaRx | Consultant | |
| Syndax | Consultant | |
| AstraZeneca | Consultant and Research Support | |
| Bristol Myers Squibb | Consultant and Research Support | |
| Genentech | Consultant and Research Support | |
| Eli Lilly | Research Support | |
| Anju Nohria, MD | AstraZeneca | Consultant |
| Boehringer Ingelheim | Consultant | |
| Takeda Oncology | Consultant | |
| Amgen, Inc. | Research Support | |
| Mark Pomerantz, MD | AstraZeneca | Research Support |
All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Activity Commercial Support
This activity is supported by educational grants from Eli Lilly and Gilead.